Target Price | $35.70 |
Price | $26.29 |
Potential |
35.79%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target Summit Therapeutics PLC Sponsored ADR 2026 .
The average Summit Therapeutics PLC Sponsored ADR target price is $35.70.
This is
35.79%
register free of charge
$46.20
75.73%
register free of charge
$12.12
53.90%
register free of charge
|
|
A rating was issued by 18 analysts: 16 Analysts recommend Summit Therapeutics PLC Sponsored ADR to buy, 1 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Summit Therapeutics PLC Sponsored ADR stock has an average upside potential 2026 of
35.79%
register free of charge
|
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 01 2025 |
UBS |
Locked
➜
Locked
|
Locked | Jul 01 2025 |
Leerink Partners |
Locked
➜
Locked
|
Locked | Jun 11 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Jun 02 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | May 02 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 15 2025 |
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 12 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 01 2025 |
Locked
UBS:
Locked
➜
Locked
|
Jul 01 2025 |
Locked
Leerink Partners:
Locked
➜
Locked
|
Jun 11 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Jun 02 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.